Clinical trials: Psoriasis, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Psoriasis
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Adult Non-infectious Uveitis
A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical research on adalimumab. The project plans to enroll 30 subjects. The safety and efficacy of adalimumab injection for adult non-infectious uveitis are being investigated.
- Trial name
- NCT07663331
- Testing
- TyboWe® Adalimumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Juvenile Psoriatic Arthritis
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
- Trial name
- NCT06100744
- Testing
- Adalimumab, Risankizumab
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Plaque Psoriasis, Psoriatic Arthritis
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy.
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis
- Trial name
- NCT06802848
- Testing
- Xeligekimab injection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Genrix Biopharmaceutical Co., Ltd
Erythrodermic Psoriasis
Efficacy of Injection Sekucinumab in Erythrodermic Psoriasis
Erythroderma is a rare and severe dermatological manifestation of a variety of diseases. The most common form of erythroderma is erythrodermic psoriasis (EP), which accounts for 1-2.25% of all psoriatic patients, with a male…
- Trial name
- NCT06801028
- Testing
- injection Sekucinumab
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Inflammatory Joint Diseases
The Norwegian Antirheumatic Drug Register
NOR-DMARD is a register-based longitudinal observational study of which the main objectives are to study the effectiveness of treatment of inflammatory joint diseases with biological disease modifying anti-rheumatic drugs…
- Trial name
- NOR-DMARD (NCT01581294)
- Where
- 6 sites in Norway
- Volunteers
- 15,000 people
- Sponsor
- Diakonhjemmet Hospital
Psoriasis
A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, tolerability and drug survival of guselkumab in high-dose and extended-interval versus standard-dose in Chinese participants with moderate to severe plaque psoriasis.
- Trial name
- NCT07532486
- Testing
- Guselkumab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Palmoplantar Pustulosis (PPP)
Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a chronic and recurrent skin disease, mainly characterized by erythema, pustules and scales on the palms and soles, often accompanied by itching and pain, which seriously affects the quality of…
- Trial name
- NCT07503652
- Testing
- Xeligekimab Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Hospital of China Medical University
Psoriasis (PsO), Randomised Controlled Trial
Sulodexide in Controlling the Recurrence of Psoriasis
This is a multicenter, randomized, double-blinded，controlled clinical trial. The purpose of the study is to evaluate the efficacy and safety of Sulodexide versus placebo in preventing psoriasis recurrence in patients with plaque…
- Trial name
- NCT06982196
- Testing
- Sulodexide
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Xijing Hospital
Psoriatic Arthritis
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
- Trial name
- NCT06865105
- Testing
- Lutikizumab, Risankizumab
- Where
- 37 sites in United States, Canada and 4 more
- Volunteers
- 120 people
- Sponsor
- AbbVie
Psoriatic Arthritis, Depression
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
The investigators seek clinically actionable understanding of the mechanisms that underlie depression in the context of immune mediated inflammatory diseases (IMIDs), delivered by a focused immune intervention study examining…
- Conditions
- Psoriatic Arthritis, Depression, Psoriatic Plaque
- Trial name
- ELATE (NCT06786936)
- Testing
- Secukinumab, Bimekizumab, Ixekizumab
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- NHS Greater Glasgow and Clyde
Crohns Disease, Colitis, Ulcerative
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile…
- Conditions
- Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
- Trial name
- TRILOGY (NCT06663332)
- Testing
- Guselkumab
- Where
- 53 sites in United States, Argentina and 16 more
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
Autoimmune Disease, Crohn Disease
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in…
- Conditions
- Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT03816345
- Testing
- Biospecimen Collection, Cabozantinib, Fluoropyrimidine
- Where
- 52 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Psoriasis Vulgaris
Psoriatic Immune Response to Tildrakizumab
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
- Trial name
- NCT05390515
- Testing
- Tildrakizumab Prefilled Syringe
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Moderate-to-severe Plaque Psoriasis
A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis
The primary objective of this study is to evaluate the efficacy and safety of HS-20137 in the treatment of participants with moderate to severe plaque psoriasis.
- Trial name
- NCT06844799
- Testing
- HS-20137
- Volunteers
- 720 people
- Sponsor
- Hansoh BioMedical R&D Company
Plaque Psoriasis
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
Psoriasis (PsO) is a systemic immune disease that affect 2-4% of the population worldwide. PsO causes tremendous burden in terms of quality of life, psychological impact, disability and work productivity of affected individuals.
- Trial name
- NCT04537689
- Testing
- Ixekizumab, Methotrexate, Cyclosporin A
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Singapore General Hospital
Arthritis, Psoriatic
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)
- Trial name
- NCT07223138
- Testing
- Sonelokimab
- Where
- 17 sites in United States
- Volunteers
- 1,560 people
- Sponsor
- MoonLake Immunotherapeutics AG
Severe Plaque Psoriasis in Chinese Children
A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint…
- Trial name
- NCT07529925
- Testing
- Adalimumab Solution for Injection
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Arthritis, Psoriatic
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had…
- Trial name
- NCT07141004
- Testing
- Guselkumab
- Where
- 11 sites in India
- Volunteers
- 100 people
- Sponsor
- Johnson & Johnson Private Limited
Moderate to Severe Plaque Psoriasis
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
This is a prospective, single-arm, multicenter, Phase IV study of 1564 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of Vunakizumab in patients with moderate-to-severe plaque…
- Trial name
- NCT06779097
- Testing
- Vunakizumab (IL-17A inhibitor)
- Where
- China
- Volunteers
- 1,564 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Healthy Volunteers
A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants
The purpose of this study is to assess the PK comparability and compare safety and tolerability of DRL_AB administered via an auto injector (AI) or prefilled syringe (PFS) in healthy male participants.
- Trial name
- NCT07744828
- Testing
- DRL_AB
- Where
- 3 sites in New Zealand
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited